The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study

The glucagon-like peptide 1 (GLP-1) agonist showed anti-hyperglycemic and anti-inflammatory effects, which may retard the risk of external eye disease. The protective effect of GLP-1 agonist and dry eye disease (DED) was found, while the relationship between GLP-1 agonist and other corneal diseases...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Ying-Chi, Peng, Shu-Yen, Chang, Chao-Kai, Lee, Chia-Yi, Huang, Jing-Yang, Hsieh, Ming-Ju, Yang, Shun-Fa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606163/
https://www.ncbi.nlm.nih.gov/pubmed/37893823
http://dx.doi.org/10.3390/healthcare11202749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606163/
https://www.ncbi.nlm.nih.gov/pubmed/37893823
http://dx.doi.org/10.3390/healthcare11202749

Ejemplares similares